Active	Status	Sponsor type	Region	Phase	Filter
12 Active 18 Inactive 30 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Stocchi, Fabrizio
VorDe-PD, NCT04301492: Tolerability, Safety and Efficacy of Vortioxetine	Recruiting	4	20	Europe	Vortioxetine	IRCCS San Raffaele Roma	Depression	07/23	07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD	Completed	3	523	Europe, US	buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo	Annovis Bio Inc., TFS Trial Form Support	Parkinson's Disease, Idiopathic	12/23	12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations	Completed	3	507	Europe, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	01/24	02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)	Completed	3	522	Europe, Canada, US, RoW	Tavapadon, PF-06649751, CVL-751, Placebo	Cerevel Therapeutics, LLC	Parkinson Disease	06/24	06/24
PROSPER, NCT06355531: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)	Recruiting	2	220	Europe, US	FNP-223, Placebo	Ferrer Internacional S.A.	Progressive Supranuclear Palsy	11/26	11/26
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy	Active, not recruiting	2	159	Europe, Japan, US	TAK-341, MEDI1341, Placebo	Takeda, AstraZeneca	Multiple System Atrophy	07/25	07/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26
TEMPO, NCT05773885: Telerehabilitation in People With Parkinson's Disease	Recruiting	N/A	40	Europe	VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy), Conventional rehabilitation	IRCCS San Raffaele Roma	Parkinson's Disease	09/23	03/24
NCT05904288: DTx Algorithms for Personalized Parkinson's Disease Treatment and Medication Plan Optimization	Completed	N/A	54	Europe	Smartwatch Garmin Vivosmart [wearable sensor], Soturi™ [digital mobile app], Clinical Assessment	Newel Health SRL, Michael J. Fox Foundation for Parkinson's Research, Mediolanum Cardio Research	Parkinson Disease	10/24	10/24
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study	Active, not recruiting	N/A	25000	Europe, Canada, US, RoW		CENTOGENE GmbH Rostock	Parkinson´s Disease	12/25	12/25
Marras, Connie
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry	Recruiting	N/A	25000	Canada, US, RoW	Lab Assay for seven genetic variants for Parkinson's Disease	Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group	Parkinson's Disease	12/24	06/25
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort	Recruiting	N/A	4500	Europe, Canada, US, RoW		Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders	Parkinson Disease	12/33	12/33